Arbutus Biopharma Corp Operating Income Loss

• Arbutus Biopharma Corp showed an increase of +50.0% in Operating Income Loss from 2024 to 2025.
• This data is from Arbutus Biopharma Corp's annual report (Form 10-K), filed with the SEC on March 23, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Arbutus Biopharma Corp's Operating Income Loss has declined by 350.2%.
• Historical annual values: Fiscal year 2025: -$38.16 million | Fiscal year 2024: -$76.32 million | Fiscal year 2023: -$78.10 million | Fiscal year 2022: -$65.46 million | Fiscal year 2021: -$73.52 million | Fiscal year 2020: -$57.81 million | Fiscal year 2019: -$143.90 million | Fiscal year 2018: -$89.78 million | Fiscal year 2017: -$110.93 million | Fiscal year 2016: -$491.64 million | Fiscal year 2015: -$103.92 million | Fiscal year 2014: -$33.43 million | Fiscal year 2013: -$12.15 million | Fiscal year 2012: -$12.95 million | Fiscal year 2011: -$10.69 million | Fiscal year 2010: -$12.52 million | Fiscal year 2009: -$8.48 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026